(Total Views: 701)
Posted On: 08/06/2020 5:40:52 PM
Post# of 153933
Re: Riztheinvestor #47601
No, I wasn't saying this.
Whether the trial will be stopped depends on which boundary they have specified in their analysis plan, 0.0294 or 0.001 or something else, to get an halt for efficacy at the interim point.
But we don't know this boundary and since on Q&A mostly morons get to ask questions like "does leronlimab have different indications?" "What about remdesivir?", or that HC Wrainwright analyst who always asks something that was answered during the presentation already, we likely won't know until the analysis has been conducted ...
In short, we don't know how effective leronlimab needs to be in order to convince FDA to stop the trial at the interim point. So it's all just speculation...
Whether the trial will be stopped depends on which boundary they have specified in their analysis plan, 0.0294 or 0.001 or something else, to get an halt for efficacy at the interim point.
But we don't know this boundary and since on Q&A mostly morons get to ask questions like "does leronlimab have different indications?" "What about remdesivir?", or that HC Wrainwright analyst who always asks something that was answered during the presentation already, we likely won't know until the analysis has been conducted ...
In short, we don't know how effective leronlimab needs to be in order to convince FDA to stop the trial at the interim point. So it's all just speculation...
(5)
(0)
